首页|Inhibiting the Otub1/phosphorylated STAT3 axis for the treatment of non-small cell lung cancer
Inhibiting the Otub1/phosphorylated STAT3 axis for the treatment of non-small cell lung cancer
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
The transcription factor STAT3 is a promising target for the treatment of non-small cell lung cancer(NSCLC).STAT3 activity is mainly dependent on phosphorylation at tyrosine 705(pSTAT3-Y705),but the modulation on pSTAT3-Y705 is elusive.By screening a library of deubiquitinases(Dubs),we found that the Otub1 increases STAT3 transcriptional activity.As a Dub,Otub1 binds to pSTAT3-Y705 and specifically abolishes its K48-linked ubiquitination,therefore preventing its degradation and promoting NSCLC cell survival.The Otub1/pSTAT3-Y705 axis could be a potential target for the treatment of NSCLC.To explore this concept,we screen libraries of FDA-approved drugs and natural products based on STAT3-recognition element-driven luciferase assay,from which crizotinib is found to block pSTAT3-Y705 deubiquitination and promotes its degradation.Different from its known action to induce ALK positive NSCLC cell apoptosis,crizotinib suppresses ALK-intact NSCLC cell proliferation and colony formation but not apoptosis.Furthermore,crizotinib also suppresses NSCLC xenograft growth in mice.Taken together,these findings identify Otub1 as the first deubiquitinase of pSTAT3-Y705 and provide that the Otub1/pSTAT3-Y705 axis is a promising target for the treatment of NSCLC.
Otub1STAT3non-small cell lung cancerCrizotinib
Zi-yang Liu、Ya-wen Zhang、Hai-xia Zhuang、Yu-jie Ou、Qiu-yun Jiang、Ping-fei Li、Yuan-ming He、Ying Ren、Xin-liang Mao
展开 >
The Key Laboratory of Advanced Interdisciplinary Studies,The First Affiliated Hospital of Guangzhou Medical University & Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China
Department of Pharmacology,College of Pharmaceutical Sciences,Soochow University,Suzhou 215123,China
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy,Xuzhou Medical University,209 Tongshan Road,Xuzhou 221004,China
NETL
NSTL
万方数据
